Abivax (ABVX) Return on Assets (2025 - 2026)
Abivax (ABVX) posted quarterly Return on Assets of 0.01% for Q1 2026, little changed year-over-year from 0.01% in Q1 2025, and down 9.55% on a QoQ basis from 0.01% in Q4 2025.
Abivax (ABVX) Return on Assets (2025 - 2026) Analysis & Trends
Abivax (ABVX) has reported Return on Assets for 2 consecutive years, with 0.01% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Assets changed 0.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), while the FY2025 annual figure was 0.01%, changed 0.0% from the prior year.
- Return on Assets came in at 0.01% for Q1 2026 at Abivax, down from 0.01% in the prior quarter.
- The five-year high for Return on Assets was 0.01% in Q4 2025, with the low at 0.01% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | - |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -0.01% |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 0.00% |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 0.00% |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 0.00% |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | - |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 0.00% |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | 0.00% |
| 10 | Abivax | - | - | - | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.01% |
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.01% |